Back to index

Cancer Chemotherapy Regimen for Osteosarcoma Cancer

 VML-A                                           osteosarcoma(108)
  vincristine..... 2.0 mg/sqm (maximum single dose 2.0 mg) IV on
                   day 1.
  methotrexate.... 7,500 mg/sqm IV over 6 h beginning 30 min after
  leucovorin...... 15 mg IV every 3 h times 8, then 15 mg orally
                   every 6 h times 8, beginning 2 h after
                   methotrexate administration is completed.
  adriamycin...... 75 mg/sqm IV every 3 weeks times 6, beginning
                   with the fifth course of VML.
  FREQUENCY....... 24 courses of VML + VML-A, cycled as follows,
                   are administered:

                   VML every week times 4, then

                   VML-A every 3 weeks times 6, then

                   VML every week times 4, then

                   VML every 3 weeks times 6, then

                   VML every week times 4.

Goorin AM.  Perez-Atayde A.  Gebhardt M.  Andersen JW.   Wilkinson RH. Delorey MJ.  Watts H.  Link M.  Jaffe N.  Frei E  3d.  et al. Weekly high-dose methotrexate and doxorubicin for
osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III. Journal of Clinical Oncology.  5(8):1178-84, 1987 Aug.
Weekly high-dose methotrexate with leucovorin rescue and vincristine (HDMTX) and doxorubicin was administered as adjuvant postoperative therapy to 46 patients with a diagnosis
of conventional high-grade nonmetastatic osteosarcoma of an extremity between July 1976 and December 1981. The primary lesions were managed by wide or radical amputation (26 patients) or by limb-sparing resection in 20 selected patients. The margins of the resections were retrospectively classified as marginal in three, wide in 16, and radical in one. The 5-year relapse-free survival (RFS) for all patients is 59% (95% confidence interval [CI], 43%, 74%) and overall
survival is 78% (95% CI, 65%, 91%). The RFS for patients initially having a limb resection procedure is 55% (95% CI, 32%, 77%) compared with 62% (95% CI, 43%, 81%) for those initially having amputations (P = .52). Using multivariate analysis, the only significant prognostic variables that predicted RFS of greater than or equal to 3 years, were the presence of moderate to marked lymphocytic infiltration of the primary tumor (P less than .002), primary site outside of the proximal humerus (P less than .005), and the absence of a predominance of osteoblastic pattern in the primary tumor (P less than .03).

Article reviewed by:

Dr. Tamer Fouad, M.D.

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us